HR Execs on the Move

Cytovia Therapeutics

www.cytoviatx.com

 
Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
James Priour
 Chief Product Officer Profile
Luca Scavo
 Chief Financial Officer Profile

Similar Companies

SBH Willow Peak

Willow Creek Behavioral Health provides mental health treatment and group therapy in Green Bay, WI. Our hospital provides innovative treatments and 24/7 access to care.

Arro Corporation

Arro Corporation is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Travanti Pharma

Travanti Pharma is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DestinationRX

DestinationRX is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).